Hartline Investment Corp Increases Stake in Eli Lilly and Company $LLY

Hartline Investment Corp boosted its position in Eli Lilly and Company (NYSE:LLY) by 5.3% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 14,494 shares of the company’s stock after acquiring an additional 734 shares during the period. Eli Lilly and Company accounts for approximately 1.5% of Hartline Investment Corp’s portfolio, making the stock its 19th largest holding. Hartline Investment Corp’s holdings in Eli Lilly and Company were worth $13,331,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Horst & Graben Wealth Management LLC boosted its position in Eli Lilly and Company by 2.8% during the first quarter. Horst & Graben Wealth Management LLC now owns 519 shares of the company’s stock worth $450,000 after purchasing an additional 14 shares during the period. Hoey Investments Inc. raised its position in shares of Eli Lilly and Company by 57.1% in the first quarter. Hoey Investments Inc. now owns 165 shares of the company’s stock valued at $152,000 after purchasing an additional 60 shares during the period. R Squared Ltd lifted its stake in shares of Eli Lilly and Company by 331.8% during the 1st quarter. R Squared Ltd now owns 2,647 shares of the company’s stock valued at $2,435,000 after buying an additional 2,034 shares in the last quarter. Resonant Capital Advisors LLC boosted its holdings in Eli Lilly and Company by 7.2% in the 1st quarter. Resonant Capital Advisors LLC now owns 6,123 shares of the company’s stock worth $5,632,000 after buying an additional 410 shares during the period. Finally, Clare Market Investments LLC bought a new position in Eli Lilly and Company in the 1st quarter worth approximately $3,877,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on LLY. Bank of America boosted their target price on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Leerink Partners lifted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Friday, June 5th. Wolfe Research reissued an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. Finally, UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,243.22.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,233.32 on Wednesday. The stock has a market cap of $1.16 trillion, a P/E ratio of 43.81, a PEG ratio of 1.49 and a beta of 0.51. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The business’s 50-day moving average price is $1,078.08 and its two-hundred day moving average price is $1,030.27. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 35.74 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan raised its price target on Eli Lilly to $1,400 from $1,300 and reiterated an overweight rating, signaling continued upside expectations for the stock. Benzinga report on JPMorgan price target raise
• Positive Sentiment: Shares hit a fresh 52-week high, reflecting momentum buying and strong investor enthusiasm around Lilly’s GLP-1 and obesity-treatment pipeline. CNBC report on Eli Lilly hitting 52-week high
• Positive Sentiment: Weak results from Kailera Therapeutics’ weight-loss pill IPO appear to have indirectly helped Lilly by reinforcing the market’s confidence in Lilly’s lead position in obesity drugs. Yahoo Finance article on Kailera setback and Lilly market cap
• Positive Sentiment: Commentary from Jim Cramer and other market-watch pieces remained constructive on biotech and Lilly’s growth story, suggesting investors still see the company as a core winner in the GLP-1 boom. 247WallSt Cramer commentary on Eli Lilly
• Neutral Sentiment: Several articles highlighted Lilly as a top healthcare stock to own and as a long-term growth story, but these were mainly opinion pieces rather than new company-specific developments. Motley Fool article on Eli Lilly stock
• Neutral Sentiment: Recent partnership and China-related business updates show Lilly is still actively managing its broader pipeline and regional strategy, but they appear less important than the obesity franchise news for today’s move. Yahoo Finance article on R&D collaboration and China rights transfer
• Negative Sentiment: Some coverage continues to point to regulatory and pricing-policy risks for Lilly, which could weigh on sentiment over time even as the stock remains strong now. Yahoo Finance article on regulatory and pricing policy challenges

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.